Drug Profile
Research programme: lymphoma therapeutics - Janssen Biotech/Weill Cornell Medical College
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Janssen Biotech; Weill Cornell Medical College
- Class
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lymphoma
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Lymphoma in USA
- 19 Jun 2014 Early research in Lymphoma in USA (unspecified route)